What is the 13F Pro Quality Score for MIRM?

13F Pro ranks Mirum Pharmaceuticals, Inc. (MIRM) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View MIRM's current score at https://13fpro.ai/company/MIRM (free sign-up required for the full ranking).

Which hedge funds own the most MIRM stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of MIRM include Frazier Life Sciences Management, L.P., Jupiter Topco, BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/MIRM as soon as new 13F filings post.

Where does 13F Pro source MIRM data?

All Mirum Pharmaceuticals, Inc. fundamentals and ownership data come directly from SEC EDGAR. Mirum Pharmaceuticals, Inc. files with the SEC under CIK 1759425. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is MIRM in?

Mirum Pharmaceuticals, Inc. (MIRM) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is MIRM research updated on 13F Pro?

MIRM's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Mirum Pharmaceuticals, Inc.(MIRM)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqmid

Institutional-grade research for retail investors

SEC EDGAR: CIK 1759425 MIRM stock profile & AI dashboard →

13F Pro Quality Score

35.0/100

Rank #2,321 of 2,961 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

95.0/100

Profitability

6.5/100

Balance Sheet

1.2/100

Earnings Quality

41.6/100

Free Cash Flow

10.7/100

Institutional Flow

44.1/100

Revenue Scale

40.9/100

Dilution Risk

12.7/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why MIRM Scores 35/100

exact factor attribution · 2026-09-11

MIRM's composite is driven by revenue growth, held back by profitability and free cash flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+9.0 pts

95th pct

Institutional flow

-0.3 pts

44th pct

Earnings quality

-0.8 pts

42th pct

Scale

-1.4 pts

41th pct

Shareholder dilution

-1.9 pts

13th pct

Earnings growth

-2.3 pts

4th pct

Capital efficiency

-4.9 pts

1th pct

Free cash flow

-5.9 pts

11th pct

Profitability

-6.5 pts

7th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

MIRM Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Mirum Pharmaceuticals, Inc. (MIRM), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MIRM at 35.0/100 on a 32-signal composite quality model, placing it at rank #2,321 of 2,961 stocks — the bottom half of the AI-ranked universe. MIRM scores in the top quartile across revenue growth (95.0). Areas of concern include balance sheet strength (1.2) and profitability (6.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 12.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Mirum Pharmaceuticals, Inc. reports quarterly revenue of $176.2M, net income of $-67.2M, free cash flow of $-44.3M. Top institutional holders of MIRM by reported 13-F value include Frazier Life Sciences Management, L.P., Jupiter Topco, BlackRock, based on the most recent SEC filings. MIRM trades on the Nasdaq exchange and files with the SEC under CIK 1759425. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MIRM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Mirum Pharmaceuticals, Inc. directly from SEC EDGAR. Mirum Pharmaceuticals, Inc.'s 13F Pro composite quality score has ranged between 8 and 56 since 2022, currently 35.0 — an improving long-term trajectory across 63 quarterly and live scoring snapshots.

✦

Fun facts about Mirum Pharmaceuticals, Inc.

Quirks, history, and lore behind MIRM — the kind of stuff that makes a stock memorable.

1
The Basics
A small-cap biopharmaceutical company listed on Nasdaq, headquartered in California, focused on developing drugs for rare liver diseases.
2
The Numbers
With revenue in the tens of millions and a lean commercial-stage operation, this company punches above its weight in a highly specialized niche most investors have never heard of.
3
The History
Founded around 2018, it quickly advanced a pipeline targeting cholestatic liver conditions — rare diseases where bile can't flow properly and patients have very few options.
4
The Secret
Its lead asset works by blocking a bile acid transporter in the gut, reducing the toxic buildup that causes debilitating itch and liver damage in children with rare genetic disorders.
5
The Lore
It scored an FDA approval for a drug targeting progressive familial intrahepatic cholestasis — a mouthful of a disease that affects only a handful of children per million births.
6
The Giveaway
Its approved drug Livmarli (maralixibat) gave kids with a devastating rare liver disease their first real shot at relief — and put this tiny pharma on the map with a ticker that sounds like a magic word.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$176.2M

Net Income

Q2 2026

$-67.2M

Free Cash Flow

Q2 2026

$-44.3M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+54.7% YoY

$521.3MFY 2025

FY22 $77.1MFY23 $186.4MFY24 $336.9MFY25 $521.3M

Net Income

+73.4% YoY

$-23.4MFY 2025

FY22 $-135.7MFY23 $-163.4MFY24 $-87.9MFY25 $-23.4M

Operating Income

+74.7% YoY

$-22.1MFY 2025

FY22 $-131.2MFY23 $-109.2MFY24 $-87.6MFY25 $-22.1M

EPS (Diluted)

+74.6% YoY

$-0.47FY 2025

FY22 $-4.02FY23 $-4.00FY24 $-1.85FY25 $-0.47

Total Assets

+25.7% YoY

$842.8MFY 2025

FY22 $352.9MFY23 $646.6MFY24 $670.8MFY25 $842.8M

Op. Cash Flow

+440.7% YoY

$55.8MFY 2025

FY22 $-120.1MFY23 $-70.9MFY24 $10.3MFY25 $55.8M

Free Cash Flow

+488.0% YoY

$54.9MFY 2025

FY22 $-120.4MFY23 $-71.1MFY24 $9.3MFY25 $54.9M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$521.3M +54.7%	$336.9M +80.8%	$186.4M +141.8%	$77.1M +302.7%	$19.1M	$0.00
Net Income	$-23.4M +73.4%	$-87.9M +46.2%	$-163.4M -20.5%	$-135.7M -61.5%	$-84.0M +18.7%	$-103.3M
Operating Income	$-22.1M +74.7%	$-87.6M +19.7%	$-109.2M +16.8%	$-131.2M +24.3%	$-173.4M -66.3%	$-104.3M
EPS (Diluted)	$-0.47 +74.6%	$-1.85 +53.8%	$-4.00 +0.5%	$-4.02 -45.1%	$-2.77	—
Total Assets	$842.8M +25.7%	$670.8M +3.7%	$646.6M +83.2%	$352.9M +19.8%	$294.7M +22.3%	$240.9M
Operating Cash Flow	$55.8M +440.7%	$10.3M +114.6%	$-70.9M +40.9%	$-120.1M +9.5%	$-132.8M -49.0%	$-89.1M
Free Cash Flow	$54.9M +488.0%	$9.3M +113.1%	$-71.1M +41.0%	$-120.4M +9.3%	$-132.8M -48.7%	$-89.3M

Get alerted when MIRM's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Mirum Pharmaceuticals, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of MIRM

Frazier Life Sciences Management, L.P.
$899.1M7,679,684 sh
Jupiter Topco LLC
$691.7M5,909,184 sh
BlackRock, Inc.
$513.9M4,390,063 sh
FMR LLC
$429.7M3,670,314 sh
PRICE T ROWE ASSOCIATES INC /MD/
$310.9M2,655,607 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$278.3M2,377,019 sh
VANGUARD CAPITAL MANAGEMENT LLC
$263.9M2,254,109 sh
STATE STREET CORP
$254.1M2,170,689 sh
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC
$164.5M1,404,741 sh
GEODE CAPITAL MANAGEMENT, LLC
$163.2M1,393,908 sh

Fund	Value	Shares
Frazier Life Sciences Management, L.P.	$899.1M	7,679,684
Jupiter Topco LLC	$691.7M	5,909,184
BlackRock, Inc.	$513.9M	4,390,063
FMR LLC	$429.7M	3,670,314
PRICE T ROWE ASSOCIATES INC /MD/	$310.9M	2,655,607
VANGUARD PORTFOLIO MANAGEMENT LLC	$278.3M	2,377,019
VANGUARD CAPITAL MANAGEMENT LLC	$263.9M	2,254,109
STATE STREET CORP	$254.1M	2,170,689
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC	$164.5M	1,404,741
GEODE CAPITAL MANAGEMENT, LLC	$163.2M	1,393,908

Companies Similar to MIRM

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

BBIO

BridgeBio Pharma, Inc.

AI score

Very similar · 30 shared holders

Frazier Life Sciences Management, L.P.Polar Capital Holdings Plc Clearbridge Investments, LLC

RYTM

RHYTHM PHARMACEUTICALS, INC.

AI score

Very similar · 28 shared holders

Polar Capital Holdings Plc Rock Springs Capital Management LP Clearbridge Investments, LLC

MDGL

MADRIGAL PHARMACEUTICALS, INC.

AI score

Very similar · 27 shared holders

WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC Polar Capital Holdings Plc Rock Springs Capital Management LP

Guardant Health, Inc.

AI score

Very similar · 32 shared holders

WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC EVENTIDE ASSET MANAGEMENT, LLC LORD, ABBETT & CO. LLC

KYMR

Kymera Therapeutics, Inc.

AI score

Very similar · 26 shared holders

BVF INC/IL EVENTIDE ASSET MANAGEMENT, LLC BAKER BROS. ADVISORS LP

CYTK

CYTOKINETICS INC

AI score

Very similar · 31 shared holders

WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC Polar Capital Holdings Plc Frazier Life Sciences Management, L.P.

SNDX

Syndax Pharmaceuticals Inc

AI score

Very similar · 17 shared holders

Candriam S.C.A.Hood River Capital Management LLC Trails Edge Capital Partners, LP

INSM

INSMED Inc

AI score

Very similar · 22 shared holders

Polar Capital Holdings Plc Clearbridge Investments, LLC WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put MIRM on your watchlist

Track score changes the day Mirum Pharmaceuticals, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is MIRM a good stock to buy?

13F Pro's AI-powered analysis of Mirum Pharmaceuticals, Inc. (MIRM) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MIRM are available on the MIRM stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. MIRM is classified as a mid company.

Which hedge funds own MIRM?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MIRM. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Mirum Pharmaceuticals, Inc.'s investment landscape.